We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
FFA
151
Farther Finance Advisors
California
$11K +$114 +3 +0.9%
PNC Financial Services Group
152
PNC Financial Services Group
Pennsylvania
$8.33K -$7.09K -186 -43%
SAM
153
Smartleaf Asset Management
Massachusetts
$6.31K +$6.17K +162 +579%
JSAM
154
J. Safra Asset Management
New York
$6.08K +$6.02K +158 +632%
LC
155
Lindbrook Capital
California
$5.61K +$381 +10 +6%
CAM
156
Close Asset Management
United Kingdom
$5K – – –
Carson Wealth (CWM LLC)
157
Carson Wealth (CWM LLC)
Nebraska
$5K +$457 +12 +10%
AAP
158
Arax Advisory Partners
Colorado
$4.72K – – –
S
159
SignatureFD
Georgia
$4.52K +$305 +8 +6%
SCM
160
Sterling Capital Management
North Carolina
$3.33K +$3.73K +98 New
QT
161
Quantbot Technologies
New York
$3.23K +$3.62K +95 New
VCM
162
Versant Capital Management
Arizona
$3.13K +$3.5K +92 New
RA
163
Rise Advisors
New York
$2.82K – – –
CFD
164
Creative Financial Designs
Indiana
$2.82K +$3.16K +83 New
BTI
165
Blue Trust Inc
Georgia
$2.18K +$2.13K +56 +1,867%
RIL
166
Rothschild Investment LLC
Illinois
$2.04K +$1.33K +35 +140%
TFGT
167
TS Financial Group (TSFG)
Illinois
$2K -$1.91K -50 -50%
Bessemer Group
168
Bessemer Group
New Jersey
$2K +$2.29K +60 New
GI
169
GAMMA Investing
California
$1.73K +$1.56K +41 +410%
SWM
170
Spire Wealth Management
Virginia
$1.7K – – –
PA
171
Parallel Advisors
California
$748 – – –
SIS
172
Strategic Investment Solutions
Illinois
$170 – – –
UB
173
UMB Bank
Missouri
$68 – – –
AssetMark Inc
174
AssetMark Inc
California
$34 – – –
SI
175
Sofinnova Investments
California
– -$20.3M -547,707 Closed
5 6
7
8 9

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.